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Background: Data suggests that males experience less toxicity and poorer survival than females treated for Ewing’s
sarcoma. We instituted an intra-patient dose escalation (DE) policy with Vincristine/Doxorubicin/Cyclophosphamide
(VDC) alternating with Ifosfamide/Etoposide (IE) based on hematological nadirs and report its feasibility and safety.
Methods: A retrospective review of adherence to DE guidelines and toxicities was conducted for patients who
received DE with VDC/IE over 3 years at a single cancer center. Absolute neutrophil counts (ANC) was collected on
days 8, 12 and 15 for cycles 1–6. DE of 10%/cycle was applied if ANC > 1.5×109/L and platelet > 100×109/L on all
blood results. The primary endpoint was the proportion of patients who received appropriate DE. The secondary
endpoint was to assess morbidity, changes in hematologic nadirs between gender and age and a comparison with
a prior cohort of ESFT patients who did not receive DE. Gender comparisons were assessed via independent
2-sample t-tests assuming unequal variances. Within cycle changes in hematologic nadirs were assessed using
repeated measures ANOVA. Relapse free survival and overall survival (OS) curves were estimated using the
Kaplan-Meier method.
Results: 23 patients were identified (mean age: 27; range 17–54). 91 decisions for DE were made (1 decision
excluded because of progressive disease) with 90% concordance with guidelines. No adverse outcomes occurred as
a result of the inappropriate escalation. Grade 3/4 febrile neutropenia (FN) during VDC and IE was 26.1% (6/23
patients) and 17.4% respectively with no difference for those who were DE. Males were less neutropenic after C1
and C3 of VDC compared to females (P-value C1 = 0.003; C3 = 0.005). VDC was associated with greater neutropenia
on day 8 whereas IE had greater neutropenia on day 12 (P-value <0.001). During VDC, a non statistical difference in
neutropenia was seen for individuals aged 15–25 (n = 13) compared with older individuals (P-value = 0.09). OS
comparison for those with localized disease with a prior cohort who were not DE showed similar outcomes
(P-value = 0.37).
Conclusions: DE is deliverable without increased adverse outcomes. Males have less myelosuppression during VDC,
and should be especially considered for DE.
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Ewing sarcoma family tumors (ESFT) are malignant tumors
of bone and soft tissue. Patients presenting with localized
disease are usually treated with multimodality approach,
given high relapse rates (80-90%) without chemotherapy
[1,2]. Modern treatment plans include neo-adjuvant and
adjuvant multi-agent chemotherapy, to target the high risk
of subclinical metastatic disease at the time of diagnosis. In
studies predominantly involving pediatric populations, this
approach leads to 5 year survival rates around 70% [3-5].
Even in patients presenting with metastatic disease, long-
term survival may be seen in 20% of patients [2]. The trad-
itional chemotherapy used in both localized and metastatic
disease is Vincristine, Doxorubicin, Cyclophosphamide al-
ternating with Ifosfamide and Etoposide (VDC/IE) [2,6],
with suggestions that the dose of doxorubicin may be re-
lated to outcome [7].
Despite a steady improvement in cancer care generally,
there has been a discouraging lack of improvement in
survival rates in adolescent and young adults (AYA) [8].
For patients diagnosed with ESFT between the ages 15–
30, survival is approximately half that of children with
males having increased mortality compared to females in
the AYA subgroup [9-11]. There has been much specu-
lation as to the reasons for these observations. The sug-
gestion that relative underdosing of AYA compared to
children may play a part is supported by data showing
that adults with pediatric-type sarcomas experience less
treatment-related toxicity compared with their younger
counterparts [10,12-14]. A meta-analysis in osteosar-
coma showed that children had higher rates of neutro-
penia compared with adolescent or adult patients, and
that dose-related toxicities including thrombocytopenia
and mucositis were strongly associated with improved
overall survival [9]. In addition to age, gender-related
differences also exist in osteosarcoma, with males ex-
periencing less myelosuppression and inferior survival
[7,9]. A retrospective study of 14,824 patients showed
that male AYA patients with osteosarcoma, Ewing sar-
coma and Hodgkin lymphoma experienced less toxicity,
lower response rates and excess mortality relative to
children and female counterparts [12]. Similar findings
correlating lack of chemotherapy-induced toxicity and
inferior outcome [15-17], have also been reported in
testis, breast and ovarian cancers [18].
These data suggest that age and gender-related differ-
ences in drug handling may account for some of the sur-
vival and toxicity differences in the AYA population. If so,
dose intensification may improve outcomes in chemosen-
sitive cancers. Accurate dosing of chemotherapy is difficult
using traditional algorithms based on body surface area
[19], with evidence for systematic underdosing [20,21].
While one study of dose escalation of alkylating agents did
not improve outcomes in Ewing sarcoma [22], increasingdose density from a 21 day cycle to a 14 day cycle with
growth factor support [23] may be associated with im-
proved survival without increased toxicity [24]. These ap-
proaches have relied on dose intensification across all
patients treated on these protocols, rather than intra-
patient dose modification to achieve a pharmacodynamic
effect. Current studies of anthracycline pharmacokinetics
and pharmacodynamics (ACTRN12609000956202) will
aid in justifying and developing strategies for “individualiz-
ing” chemotherapy, enabling the use of readily available
surrogate markers such as the degree of myelosuppres-
sion, or measures of the antiproliferative activity of drugs,
to guide dose-adjustments [25,26].
In the absence of more accurate algorithms for chemo-
therapy dosing, one practical solution for personalized,
intra-patient dosing is “toxicity-adjusted” dosing [20]. In
2009, we implemented a policy at the Peter MacCallum
Cancer Centre to individualized dose escalation of chemo-
therapy in Ewing sarcoma patients, using nadir bloods
counts as the primary measure of a dose-related pharma-
codynamic effect. We now report on our dose escalation
(DE) policy over a 3 year period to assess overall deliver-
ability, safety and treatment related toxicity.
Methods
The primary objective was to assess the proportion of patients
that received DE and the proportion of DE decisions that
were appropriate according to the protocol. The secondary
objective was to assess rates of serious complications for the
entire group, investigate gender and age related differences in
neutrophil and platelet nadirs, assess subsequent neutrophil
and platelet nadirs for those who underwent dose escalation,
and calculate relapse free survival (RFS) and overall survival
(OS). In order to assess RFS and OS, a comparison was per-
formed with a prior cohort of ESFT with localized disease
treated with the same regimen of VDC/IE, but prior to the
initiation of our dose escalation policy. This study was ap-
proved by the Institutional Review Board of Peter MacCallum
Cancer Centre for retrospective data collection.
Chemotherapy was delivered for ESFT every 3 weeks
with vincristine (2 mg), doxorubicin (75 mg/m2), cyclo-
phosphamide (1200 mg/m2) D1 alternating with ifosfa-
mide (1800 mg/m2) and etoposide (100 mg/m2) D1-5 [2].
Blood counts were taken on Day 8, 12 and 15 for the first
6 cycles of chemotherapy and dose escalation (DE) was
implemented if the neutrophil and platelet count did not
fall below 1.5×109/L or 100×109/L, respectively, in the ab-
sence of non-hematologic toxicities of concern. Although
these hematological cut-offs have not been validated in
prospective trials, these values have been suggested in the
literature in recommendations for “toxicity adjusted dos-
ing” [15,18]. Dose escalation involved increasing the BSA
calculated dose of all chemotherapy agents, except vincris-
tine, by 10% for all equivalent subsequent cycles. Given





Median age (range) 23 (17 – 54)
Median age female 21 (17 – 54)










Axial trunk 2 (9%)
Chest wall 3 (13%)
Other 1 (4%)
BSA
Female 1.79 (SD ± 0.22)
Male 1.94 (SD ± 0.15)
Table 2 Number of patients who received dose escalation
during VDC/IE
Escalated Dose unchanged Dose reduced Number
VDC
C1 23
C3 10 10 3 23
C5 3 19 1 23
Any cycle 10 10 3 23
IE
C2 23
C4 10 11 2 23
C6 3 19 0 22
Any cycle 12 9 2 23
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to DE decision for cycle 3 and 4, whereas nadir counts for
cycle 3 and 4 led to a DE decision in cycle 5 and 6. De-
escalation occurred on the basis of both hematological
and non-hematological toxicities at the discretion of the
treating physician.
Inclusion
All patients with ESFT (including peripheral primitive
neuroectodermal tumor, Askin’s tumors, Ewing’s sarcoma,
desmoplastic small round cell tumor) who underwent
cytotoxic chemotherapy at Peter MacCallum with VDC/IE
between March 2009 and August 2012 were included.
Statistical analysis
Analysis of primary endpoints and secondary endpoints
was performed on an intention to treat basis. To address
the primary objective, the proportion of patients who re-
ceived DE was calculated for each of cycles 3 – 6 separ-
ately as well as for any VDC cycle (3 and/or 5) and any
IE cycle (4 and/or 6). To evaluate adherence, the propor-
tion of treatment decisions that were appropriate ac-
cording to the DE protocol was calculated.
To address the secondary objectives, the proportion of
patients reporting grade 3/4 febrile neutropenia in each
of the VDC and IE cycles was calculated. Comparisons
between males and females in terms of neutrophil and
platelet nadirs in cycles 1 – 4 were investigated using in-
dependent 2-sample t-tests assuming unequal variances.
Within cycle changes in neutrophil and platelet counts
as well as between cycle changes in neutrophil and
platelet nadirs were assessed using repeated measures
ANOVA. Overall survival was measured as the time
from first chemotherapy until death and relapse-free sur-
vival was measured from time of first chemotherapy
until date of relapse. Patients were censored at the last
date they were known to be alive and relapse-free re-
spectively. OS and RFS curves were estimated using the
Kaplan-Meier product-limit method. OS and RFS com-
parison to the prior historical cohort was assessed using
the logrank test. A P-value of <0.05 was considered sta-
tistically significant. Statistical analysis was performed
using Excel, GraphPad Prism 6 and R version 2.15.2
software.
Results
Between 2009 and 2012, 23 patients were treated on the
DE protocol with a median follow up of 2.3 (0.7 – 3.4)
years. Baseline demographics are shown in Table 1. In
total, 91 events for consideration of dose escalation oc-
curred (1 decisions was excluded because of progressive
disease). This is presented in Table 2. There were 3 pa-
tients during VDC that were escalated twice. Although
not statistically significant, more males had DE thanfemales during VDC (7/13 vs 3/10), but not during IE
(7/13 vs 5/10).
Protocol adherence was recorded at 90%. Nine events of
non-adherence to the protocol were recorded (7 events
of inappropriate escalation (7.7%) and 2 events of missed
escalation (2.2%); details of inappropriate escalation are
shown in Additional file 1: Table S1). No serious adverse
outcomes occurred as a result of the inappropriate escal-
ation. The rate of Grade 3/4 febrile neutropenia (FN) dur-
ing VDC was 26.1% (6/23 patients) with median length of
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sions. The rate of Grade 3/4 FN for IE was 17.4% (4/23 pa-
tients) with a median LOS of 4 days (3–7) and 1 ICU
admission. The ICU stay occurred in a patient who was
appropriately not dose-escalated. There were no deaths
related to chemotherapy and only 1 patient received a
platelet transfusion (during IE). There were no additional
documented grade 3/4 toxicities documented in those
who underwent dose escalation.
Neutrophil nadirs by gender for cycle 1 – 4 are shown
in Table 3. Males were statistically significantly less
neutropenic after C1 and C3 of VDC compared to females
(P-value C1 = 0.003; C3 = 0.005). VDC was associated with
greater neutropenia on day 8 (ANC: D8: 0.98 ± 0.97 ×
109/L, P-value <0.001) whereas IE had greater neutropenia
on day 12 (ANC: D12: 3.74 ± 3.04 × 109/L, P-value <0.001).
Although not statistically significant, there was also a
trend for less thrombocytopenia during VDC in males
(data not shown, P-value = 0.11). After cycle 1 of VDC, in-
dividuals aged 15–25 (n = 13) had lower neutrophil nadirs
compared with older individuals (mean difference = 0.62 ×
109/L, P-value = 0.15) although this was not statistically
significant. Differences in cytopenia in IE dosing according
to gender were only seen in cycle 4 (mean difference =
2.31 × 109/L, P-value = 0.05) (Table 3).
Although the numbers were too small to achieve stat-
istical significance, dose escalation, whether appropriate
or not, was associated with a reduction in neutrophil
count in subsequent cycles. For those who received dose
escalation in cycle 1 of VDC, the mean nadir ANC de-
creased from 1.59 ± 1.22 × 109/L to 1.29 ± 1.07 × 109/L in
cycle 3, and 1.04 ± 0.9 × 109/L in cycle 5 (P-value = 0.29).
For IE cycles, those who received dose escalation after
cycle 2 showed a decrease from 4.82 ± 1.88 × 109/L to
2.10 ± 1.8 × 109/L in cycle 4. Using current dosing algo-
rithms, dose escalation resulted in a trend to malesTable 3 Gender related difference in nadir blood counts after
Gender
Male Fe
N Mean SD N M
Neutrophil nadir
VDC
Cycle 1 13 1.56 1.35 9 0
Cycle 3 12 1.59 1.08 9 0
IE
Cycle 2 13 3.77 2.70 10 4
Cycle 4 12 3.17 3.54 9 0
Dose intensity (%)
VDC 13 107 9 10
IE 13 105 7 10 1
P–values correspond to comparisons between genders. Dose intensity of VDC and Ireceiving a higher relative dose intensity of VDC and IE
compared to females (VDC: 107% vs 98%, P-value = 0.12;
IE: 105% vs 102%, P-value = 0.49).
To compare overall cancer-related outcomes between
the traditional BSA associated chemotherapy dosing and
the toxicity-adapted dose escalation protocol, we com-
pared the RFS and OS between treated patients with
localized disease before (1995–2004) and during (2009–
2013) the introduction of the DE policy. The baseline
characteristics of this historical comparator group were
similar to our cohort (An additional file shows this in
more detail [see Additional file 2: Table S2]) and patients
with DSRCT and metastatic disease were excluded from
this analysis. The 2 year RFS in the dose escalation co-
hort was 88%, compared to 63% in the historical com-
parator cohort (HR = 0.33, 95% CI: (0.07-1.56); P-value =
0.14) and 2 year overall survival was 88% vs 75% in the
historical comparator cohort (HR = 0.48, 95% CI: (0.09-
2.46) P-value = 0.37 (Figures 1 and 2). When making
comparisons in our cohort group only, there was no
statistically significant difference in RFS (P-value = 0.29)
and OS (P-value = 0.31) when separated by those who
have had DE (for either VDC or IE) compared to those
who did not in patients with localized disease.
Discussion
The key finding in this study is that individualized dose es-
calation of chemotherapy in ESFT is feasible in a single
sarcoma unit. Less neutropenia was observed in males,
and perhaps in older patients, during the anthracycline
cycles, suggesting that BSA-based dosing alone may not
be adequate in males. The protocol compliance rate was
90%. Given the experimental nature of a toxicity-adjusted
protocol, we continually reviewed the safety and compli-
ance after implementation of the protocol. Importantly,






.16 0.19 1.40 (0.57, 2.21) 0.003
.42 0.56 1.17 (0.40, 1.93) 0.005
.40 4.59 −0.63 (−4.14, 2.88) 0.71
.86 1.18 2.31 (−0.04, 4.66) 0.05
98 16 9 (−3, 22) 0.12
02 11 3 (−5, 11) 0.49
E is compared to baseline.
Figure 1 Relapsed-free survival for localized ESFT compared between those who underwent a DE policy (2009 – 2012) compared with
a prior cohort who did not have a DE policy (1995 – 2004) showing a HR = 0.33 (95% CI: (0.07 – 1.53) P-value 0.14).
Figure 2 Overall survival for localized ESFT compared between those who underwent a DE policy (2009 – 2012) compared with a prior
cohort who did not have a DE policy (1995 – 2004) showing a HR = 0.48 (95% CI: (0.09 – 2.46) P-value 0.37).
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and OS comparison to the prior ESFT cohort suggests that
dose escalation is not associated with worse overall out-
comes for patients with localized primary ESFT. Clearly,
safe dose escalation requires a formal program with strictly
defined criteria for escalation, close monitoring of nadir
blood counts, and patient selection limited to those with-
out other dose-related toxicities or co-morbid illnesses.
Given this study showed gender and age related differences
in cytopenia, it is arguable that dose escalation should be
especially considered in older males during the anthracy-
cline component of treatment (Cycle 3 or 5 based on C1
nadir). Additionally, variation was seen in the timing of
neutropenia nadirs, which may have ramifications for the
timing of pegylated filgrastim delivery.
It is important to put these findings into context given
evidence for gender- and age-related difference in toxicity
and outcome in chemo-sensitive cancers such as ESFT
[12]. Although the peak incidence of ESFT is during the
AYA years, these patients have a worse survival compared
to a pediatric population [27]. The reasons behind this
comprise a combination of biological differences [27,28],
delayed diagnosis, poorer treatment compliance [29,30],
psychosocial overlay and limited involvement in clinical
trials [31,32]. With regards to biological differences, in the
EURO-Ewing 99 protocol [10], increasing age and male
gender was associated with less toxicity using VIDE
chemotherapy, a protocol similar to VDC/IE. Additionally,
gender related differences have previously been described
in hodgkins lymphoma [33], osteosarcoma [9,34,35] and
ewings sarcoma [12,36,37]. A meta-analysis in osteosar-
coma confirmed differences in outcome related to gender
and age and showed improved outcomes in females, and
those with Grade 3/4 mucositis [9]. Interestingly, it also
confirmed the results of our study showing increased mye-
losuppression in the younger age group although given
our small numbers, this was not statistically significant.
Collectively, this data suggests a better understanding of
cytotoxic pharmacology is needed in the AYA population
[28,38], and may be used to improve cancer outcomes.
Adolescent and young adult patients undergo gender-
specific pubertal changes in body composition, size and
hormonal status, which may alter the pharmacokinetic/
pharmacodynamic properties of chemotherapy [38]. Young
women have significant increase in fat mass during ado-
lescent years, with subsequent higher body fat than men
[39]. Higher fat distribution has effects on drug clearance
and volume of distribution [28,40] which may cause varia-
tions in the dose of chemotherapy delivered. That being
said, a large pediatric study in ALL showed no differences
in toxicity, survival or PK data in the obese patient [41]. It
is difficult to isolate drug-specific effects in complex,
multi-drug chemotherapeutic regimens, and it is import-
ant to recognize that different drugs may demonstratedifferent pharmacologic profiles in the AYA population.
Nearly all the benefit of methotrexate’s use in osteosarcoma
has been demonstrated in patients under the age of 40 [42]
and doxorubicin, a key component of regimens used to
treat ESFT, osteosarcoma and hodgkins disease, demon-
strates significant pharmacokinetic variation according to
gender and body habitus [43,44]. It is possible that the in-
ferior outcomes of EFST in older males may be attributed
to relative doxorubicin under-dosing of these individuals.
Given the inherent inaccuracies in current dosing al-
gorithms, and the importance of chemotherapy to cure
for chemo-sensitive cancers, intra-patient dose modifica-
tion based on markers of toxicity provides a practical
strategy for individually tailored dosing [25,26]. In this
context, this limited study suggests gender- and poten-
tially age-related differences in hematological nadirs, and
that intra-patient dose escalation appears safe and feas-
ible. It is important to note that this retrospective study
only comprises 23 patients, with relatively short follow
up. In particular, the non-significant trend to improved
RFS and OS in the dose escalation group will require lar-
ger numbers of patients and longer follow up. Addition-
ally, we did not assess long-term morbidity, including
the potential for cumulative anthracycline cardiotoxicity
in a young population.Conclusion
Individualized, toxicity-adapted dosing of chemotherapy,
added to an initial calculation of dosing based on BSA-
alone, aims to correct the gender and age related disparity
in outcomes, without relying on new chemotherapeutic
agents. Pharmacological data in this age group is lacking
[28] and adequate dose–response is critical for chemo-
sensitive diseases such as ESFT, germ cell tumors and
Hodgkin’s in maximizing outcome where a dose–response
relationship exists. The key finding in this study is that in-
dividualized dose escalation of chemotherapy in ESFT is
feasible in a single sarcoma unit without increased adverse
outcomes. Additionally we have showed that less neutro-
penia was observed in males, and perhaps in older pa-
tients, during the anthracycline cycles and should be
especially considered for DE. Given the rarity of ESFT pre-
sents significant statistical challenges in stratifying gender
and age differences, pharmacological endpoints should be
designed into future prospective chemotherapy trials.
Additional files
Additional file 1: Table S1. Description of patients who inappropriately
received dose escalation.
Additional file 2: Table S2. Comparison of baseline demographics with
for patients with localized disease who underwent a DE policy (2009 – 2012)
compared with a prior cohort who did not have a DE policy (1995 – 2004).
Patients in both cohorts were treated with alternating VDC/IE.
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